Omalizumab prevents anaphylaxis and improves symptoms in systemic mastocytosis: Efficacy and safety observations. Issue 1 (27th July 2017)

• Record Type: Journal Article
• Authors: Broesby‐Olsen, S.; Vestergaard, H.; Mortz, C. G.; Jensen, B.; Havelund, T.; Hermann, A. P.; Siebenhaar, F.; Møller, M. B.; Kristensen, T. K.; Bindslev‐Jensen, C.
• Is Part Of: Allergy. Volume 73:Issue 1(2018)
• Page Start: 230
• Page End: 238
• Publication Date: 2017-07-27
• Subjects: anaphylaxis -- KIT D816V -- mast cell disorders -- mastocytosis -- omalizumab -- systemic mastocytosis -- tryptase; Allergy -- Periodicals; 616.97
• DOI: 10.1111/all.13237
• Languages: English
• ISSNs: 0105-4538

Abstract

Abstract: Background: Patients with systemic mastocytosis (SM) may suffer from mast cell (MC) mediator‐related symptoms insufficiently controlled by conventional therapy. Omalizumab is an established treatment in other MC‐driven diseases, but experiences in SM are limited. Objective: To assess the efficacy and safety of omalizumab in SM. Methods: In our patient cohort, we evaluated all SM patients treated with omalizumab. A physician global assessment of type and severity of symptoms was performed at baseline, at 3 and 6 months and at latest follow‐up. Quality of life was assessed by visual analogue scale. S‐tryptase and KIT D816V allele burden were monitored. Results: A total of 14 adult SM patients (10 ISM, 2 BMM, 1 SSM, and 1 ASM‐AHN) received omalizumab with a median duration of 17 months (range: 1‐73 months). One patient was excluded due to concomitant cytoreductive therapy. In the remaining 13 patients, we observed a significant reduction in symptoms, with complete symptom control in five (38.5%), major response in three (23.1%), and a partial response in three (23.1%) patients, whereas two patients (15.4%) withdrew due to subjective side‐effects at first dose. The treatment was most effective for recurrent anaphylaxis and skin symptoms, less for gastrointestinal, musculoskeletal, and neuropsychiatric symptoms. Patient‐reported quality of life showed significant improvement. No significant changes in s‐tryptase/ KIT D816V allele burden were observed. No severe adverse events were recorded. Conclusions: Omalizumab appears to be a promising treatment option in SM, effectively preventing anaphylaxis and improving chronic MC mediator‐related symptoms, insufficiently controlled by conventional therapy. Controlled studies are needed to substantiate findings.